Related Experiment Video
Updated: May 14, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Research in progress: put the orphanage out of business
Andrew Bush1, Gisela Anthony, Angelo Barbato
1Department of Paediatric Respiratory Medicine, National Heart and Lung Institute, Imperial College, , London, UK.
Insights
This study standardizes the evaluation of rare pediatric interstitial lung disease (ILD) across Europe. It aims to establish consensus on treatment and conduct the first randomized controlled trial for pediatric ILD.
Area of Science:
- Pediatric Pulmonology
- Rare Diseases
- Clinical Research
Background:
- Pediatric interstitial lung disease (ILD) is a rare and heterogeneous group of conditions.
- Limited patient numbers in single centers hinder research progress and treatment standardization.
Purpose of the Study:
- To standardize the evaluation of pediatric ILD across Europe.
- To establish consensus on treatment protocols and standard operating procedures.
- To facilitate the first randomized controlled trial for pharmacological treatments in pediatric ILD.
Main Methods:
- Establishing pan-European multidisciplinary expert panels.
- Collaborating with patient groups to define treatment endpoints and biomarkers.
- Creating a Europe-wide biobank for mechanistic studies.
Main Results:
- (Not yet available in the abstract)
Conclusions:
- Standardization of evaluation and treatment protocols is crucial for advancing pediatric ILD research.
- Pan-European collaboration and biobanking will support mechanistic studies and clinical trials.
Abstract:
Paediatric interstitial lung disease (ILD) is rare and diverse, meaning no single centre will see sufficient children to perform the studies needed to make progress. This EU FP-7 grant will standardise the evaluation of these rare conditions by establishing pan-European multidisciplinary expert panels and establish consensus on treatment protocols and standard operating procedures across Europe. We will work with patient groups to determine optimal treatment end-points and biomarkers. A biobank will be established as a Europe-wide resource for mechanistic studies. Ultimately we aim to do the first randomised controlled trial of a pharmacological treatment in paediatric ILD.
More Related Videos
06:16Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
08:10Neuroimaging Field Methods Using Functional Near Infrared Spectroscopy (NIRS) Neuroimaging to Study Global Child Development: Rural Sub-Saharan Africa
Published on: February 2, 2018
Related Concept Videos
Ethics in Research
Archival Research
Robbers Cave
Investigation of Disease Outbreaks
Parental Care
Reproductive Cloning
Somatic Cell Nuclear Transfer
In SCNT, an egg cell is taken from an animal and its nucleus is removed, creating an enucleated egg. Then a somatic cell—any cell that is not a sex...